ADAP

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.0076
Percentage change 3.14	%

Peers: IOVA FATE ALLO ADPT BLRX CGEN AFMD IMTX TPST

| Held by: SPDW GWX FESM

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.27	Insider Own	11.33%	Shs Outstand	257.85M	Perf Week	3.22%
Market Cap	64.46M	Forward P/E	-	EPS next Y	-0.13	Insider Trans	-0.62%	Shs Float	228.63M	Perf Month	-13.43%
Enterprise Value	53.61M	PEG	-	EPS next Q	-0.05	Inst Own	34.07%	Short Float	2.00%	Perf Quarter	-18.03%
Income	-69.49M	P/S	0.36	EPS this Y	-75.44%	Inst Trans	-22.55%	Short Ratio	4.06	Perf Half Y	-54.87%
Sales	180.20M	P/B	-	EPS next Y	-50.43%	ROA	-33.40%	Short Interest	4.56M	Perf YTD	-53.59%
Book/sh	-0.15	P/C	1.08	EPS next 5Y	-24.90%	ROE	-273.36%	52W High	1.48 -83.11%	Perf Year	-76.19%
Cash/sh	0.23	P/FCF	-	EPS past 3/5Y	34.83% 26.53%	ROIC	-1045.00%	52W Low	0.20 28.14%	Perf 3Y	-85.63%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	207.12% 175.28%	Gross Margin	93.44%	Volatility	7.28% 7.32%	Perf 5Y	-97.36%
Dividend TTM	-	EV/Sales	0.30	EPS Y/Y TTM	62.93%	Oper. Margin	-31.13%	ATR (14)	0.02	Perf 10Y	-98.60%
Dividend Ex-Date	-	Quick Ratio	1.79	Sales Y/Y TTM	883.05%	Profit Margin	-38.56%	RSI (14)	45.87	Recom	2.50
Dividend Gr. 3/5Y	- -	Current Ratio	2.02	EPS Q/Q	7.24%	SMA20	-2.12%	Beta	2.23	Target Price	1.44
Payout	-	Debt/Eq	-	Sales Q/Q	28.87%	SMA50	-7.53%	Rel Volume	0.58	Prev Close	0.24
Employees	506	LT Debt/Eq	-	Earnings	May 13 BMO	SMA200	-52.75%	Avg Volume	1.13M	Price	0.25
IPO	May 06, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	64.79% 3.21%	Trades		Volume	452,033	Change	3.14%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-25	Downgrade	Mizuho	Outperform → Neutral	$0.50
Jul-30-24	Initiated	H.C. Wainwright	Buy	$4
May-30-24	Initiated	Scotiabank	Sector Outperform	$3.15
Mar-24-23	Initiated	Bryan Garnier	Buy	$3.60
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$5
Nov-09-22	Upgrade	Mizuho	Neutral → Buy	$9
May-28-21	Initiated	Barclays	Underweight	$4
Apr-22-20	Initiated	Mizuho	Neutral	$3
Aug-02-19	Downgrade	Guggenheim	Buy → Neutral
May-31-19	Initiated	ROTH Capital	Buy
May-30-19	Resumed	Citigroup	Buy
May-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform	$12 → $5
Mar-17-17	Initiated	Wells Fargo	Market Perform
Oct-24-16	Downgrade	BofA/Merrill	Neutral → Underperform
Sep-30-16	Initiated	Raymond James	Outperform	$16
Feb-25-16	Initiated	Citigroup	Buy	$15
Jun-01-15	Initiated	Leerink Partners	Outperform	$24
Jun-01-15	Initiated	Guggenheim	Buy
Jun-01-15	Initiated	BofA/Merrill	Neutral

Show Previous Ratings

Jun-26-25 09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
May-14-25 03:05AM	Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch ... (GuruFocus.com) +8.80%
May-13-25 07:30AM	Adaptimmune Reports Q1 Financial Results and Provides Business Update (Newsfile) -15.31%
May-12-25 09:48AM	What To Expect From Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings (GuruFocus.com)
May-07-25 12:00PM	Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025 (Newsfile)
12:05PM	Loading…
Mar-21-25 12:05PM	Earnings To Watch: Adaptimmune Therapeutics PLC (ADAP) Reports Q4 2024 Result (GuruFocus.com)
03:01AM	Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ... (GuruFocus.com)
Mar-20-25 12:10PM	Adaptimmune targets $400M sarcoma franchise peak sales by 2027 (SeekingAlpha) -37.65%
12:10PM	Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:00AM	Adaptimmune Provides Q4 and Full Year 2024 Business Update (Newsfile)
Mar-19-25 06:00PM	Here's the major earnings before the open tomorrow (SeekingAlpha)
Mar-18-25 07:00AM	From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines (FastCompany)
Mar-12-25 04:54PM	Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025 (Newsfile)
Jan-30-25 04:00PM	Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 (Newsfile)
Jan-13-25 08:00AM	Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS) (Newsfile)
07:30AM	Loading…
Dec-19-24 07:30AM	Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK (Newsfile)
Dec-02-24 04:00PM	First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel) (Newsfile)
Nov-15-24 05:00AM	Halozyme bids for Evotec; BeiGene gets a new name (BioPharma Dive)
Nov-14-24 11:55AM	Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints (Pharmaceutical Technology) -23.28%
02:15AM	Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ... (GuruFocus.com)
Nov-13-24 04:05PM	Adaptimmune Reports Q3 2024 Financial and Business Updates (Newsfile)
09:00AM	Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial (Newsfile)
Nov-05-24 09:19AM	Adaptimmune to Participate in Scientific and Medical Conferences this November and December (Newsfile)
Oct-31-24 05:20PM	Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024 (Newsfile) +10.23%
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire) -5.41%
Aug-28-24 08:00AM	Adaptimmune to Participate in Two Bank Conferences this September (Newsfile)
Aug-12-24 07:00AM	Adaptimmune Reports Q2 2024 Financial and Business Updates (Newsfile) +9.82%
Aug-09-24 07:13AM	Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval (Pharmaceutical Technology)
Aug-05-24 08:00AM	Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024 (Newsfile) -16.24%
11:53AM	Loading…
Aug-02-24 11:53AM	Adaptimmunes Tecelra gains accelerated approval for synovial sarcoma (Pharmaceutical Technology) -7.87%
08:46AM	FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade (Benzinga)
06:54AM	First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer (BioPharma Dive)
Aug-01-24 08:20PM	Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor (Business Wire)
Jul-24-24 11:13PM	Why Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now? (Insider Monkey) +5.69%
Jul-03-24 11:11AM	3 Biotech Moonshots With Imminent Catalyst Potential (InvestorPlace)
06:00AM	5 FDA decisions to watch in the third quarter (BioPharma Dive)
Jun-03-24 12:00PM	Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise (Newsfile) -5.31%
May-31-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +11.88%
May-30-24 04:01PM	Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications (GlobeNewswire)
04:01PM	Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications (Newsfile)
May-17-24 06:49AM	Mizuho Slashes Price Target on Adaptimmune Therapeutics to $3 From $9, Keeps Buy Rating (MT Newswires) -7.50%
May-16-24 08:18AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-15-24 12:53PM	ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +7.83%
11:07AM	Adaptimmune Therapeutics Enters Into $125 Million Term Loan Facility With Hercules Capital (MT Newswires)
07:30AM	Adaptimmune Reports Q1 2024 Financial and Business Updates (Newsfile)
07:00AM	Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital (Newsfile)
May-01-24 12:00PM	Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024 (Newsfile)
Apr-23-24 07:45AM	Garry Menzel joins GHO Capital as Operating Partner (GlobeNewswire) +12.87%
Apr-15-24 02:12PM	Adaptimmune (ADAP) Down on End of Collaboration With Roche (Zacks) -9.48%
Apr-12-24 08:00AM	Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated (Newsfile) -10.08%
05:37AM	Roche, Adaptimmune part ways on cell therapy research (BioPharma Dive)
Mar-27-24 07:30PM	Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet (Newsfile)
Mar-07-24 01:42PM	Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
08:24AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 12:52PM	ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) +17.12%
07:00AM	Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates (Newsfile)
Feb-27-24 08:00AM	Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise (Newsfile)
Feb-21-24 04:00PM	Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024 (Newsfile) +19.05% -8.00%
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey)
Feb-13-24 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know (Zacks) +7.11%
Jan-31-24 04:44PM	Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review (Newsfile) +9.74%
Jan-30-24 01:02PM	Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC (GuruFocus.com) +10.18%
Jan-16-24 11:17AM	Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why (Zacks) -13.72%
Jan-04-24 07:37AM	Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference (Newsfile) +12.40%
Dec-06-23 07:00AM	Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma (Newsfile)
Nov-30-23 10:52AM	Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND (Zacks)
Nov-29-23 08:00AM	Adaptimmune Receives Transfer of IND for Lete-cel Program (Newsfile) +11.66%
Nov-13-23 09:35AM	Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:35AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:30AM	Adaptimmune Reports Third Quarter Financial Results and Business Update (Newsfile) -5.57%
07:05AM	Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy (Newsfile)
Nov-07-23 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Oct-31-23 08:00AM	Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS (Newsfile)
08:00AM	Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control (Newsfile)
Oct-27-23 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
Oct-25-23 08:06AM	Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023 (Newsfile)
Oct-23-23 04:15AM	Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO (Newsfile) +6.25%
Sep-11-23 08:00AM	Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development (Newsfile) +8.81%
Aug-09-23 07:29AM	Adaptimmune Reports Second Quarter Financial Results and Business Update (Newsfile)
Aug-03-23 01:24PM	Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023 (Newsfile)
Jul-28-23 12:30PM	Adaptimmune (ADAP) to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-20-23 07:28AM	Investors in Adaptimmune Therapeutics (NASDAQ:ADAP) from five years ago are still down 90%, even after 12% gain this past week (Simply Wall St.) -10.10%
Jul-16-23 08:18PM	Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains? (Zacks)
Jun-29-23 09:18AM	Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7% (Zacks)
Jun-26-23 11:23AM	AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval (Zacks)
11:15AM	Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data (Zacks)
Jun-23-23 09:15AM	Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal (Zacks)
Jun-22-23 09:40AM	Amgen's (AMGN) Blincyto sBLA Gets FDA Nod in Treating Leukemia (Zacks)
Jun-19-23 10:18AM	GSK Announces Extension of FDA Review for Rare Blood Therapy (Zacks)
Jun-16-23 08:39AM	Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study (Zacks)
Jun-15-23 09:43AM	Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall (Zacks)
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-13-23 10:14AM	AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review (Zacks)
Jun-12-23 10:00AM	Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies (Zacks) +5.33%
09:48AM	AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies (Zacks)
Jun-09-23 10:52AM	Merck's (MRK) Keytruda for Liver Cancer to Undergo FDA Review (Zacks)
Jun-06-23 06:50AM	Dr. Reddy's (RDY) Meets Goals in Actemra Biosimilar Study (Zacks)
Jun-05-23 11:40AM	Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros (Zacks)
10:22AM	Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study (Zacks)

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Norry Elliot	Chief Medical Officer	Jan 17 '25	Sale	0.58	5,584	3,243	7,510	Jan 17 09:17 PM
Lunger John	Chief Patient Supply Officer	Jan 17 '25	Sale	0.58	5,584	3,243	7,510	Jan 17 09:17 PM
Bertrand William C JR	Chief Operating Officer	Jan 17 '25	Sale	0.58	5,584	3,243	7,510	Jan 17 09:16 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 17 '25	Sale	0.58	30,601	17,773	44,327	Jan 17 09:15 PM
Norry Elliot	Chief Medical Officer	Jan 17 '25	Proposed Sale	0.58	5,584	3,243		Jan 17 03:07 PM
Lunger John	Chief Patient Supply Officer	Jan 17 '25	Proposed Sale	0.58	5,584	3,243		Jan 17 02:59 PM
Bertrand William C JR	Chief Operating Officer	Jan 17 '25	Proposed Sale	0.58	5,584	3,243		Jan 17 02:50 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 17 '25	Proposed Sale	0.58	30,601	17,772		Jan 17 02:42 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 13 '25	Sale	0.59	30,473	17,915	17,801	Jan 15 04:19 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 15 '25	Sale	0.57	29,096	16,724	41,582	Jan 15 04:19 PM
Piccina Cintia	Chief Commercial Officer	Jan 15 '25	Sale	0.57	12,991	7,467	18,421	Jan 15 04:18 PM
Norry Elliot	Chief Medical Officer	Jan 13 '25	Sale	0.59	12,392	7,285	5,845	Jan 15 04:17 PM
Norry Elliot	Chief Medical Officer	Jan 15 '25	Sale	0.57	9,803	5,635	13,756	Jan 15 04:17 PM
Lunger John	Chief Patient Supply Officer	Jan 13 '25	Sale	0.59	9,739	5,726	5,845	Jan 15 04:16 PM
Lunger John	Chief Patient Supply Officer	Jan 15 '25	Sale	0.57	9,803	5,635	13,756	Jan 15 04:16 PM
Bertrand William C JR	Chief Operating Officer	Jan 13 '25	Sale	0.59	9,739	5,726	5,845	Jan 15 04:15 PM
Bertrand William C JR	Chief Operating Officer	Jan 15 '25	Sale	0.57	9,803	5,635	13,756	Jan 15 04:15 PM
Bertrand William C JR	Chief Operating Officer	Jan 13 '25	Proposed Sale	0.59	9,739	5,726		Jan 15 04:01 PM
Piccina Cintia	Chief Commercial Officer	Jan 15 '25	Proposed Sale	0.57	12,991	7,467		Jan 15 03:55 PM
Norry Elliot	Chief Medical Officer	Jan 13 '25	Proposed Sale	0.59	12,392	7,286		Jan 15 03:50 PM
Lunger John	Chief Patient Supply Officer	Jan 13 '25	Proposed Sale	0.59	9,739	5,726		Jan 15 03:43 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 13 '25	Proposed Sale	0.59	30,473	17,917		Jan 15 03:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Adaptimmune Therapeutics Plc ADR

Upgrade your FINVIZ experience